

CITATION REPORT

List of articles citing

The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer

DOI: 10.1111/j.1464-410x.2007.06931.x
BJU International, 2007, 100, 1396-401.

Source: <https://exaly.com/paper-pdf/42849769/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
54	Effect of insulin-like growth factor-1 on pituitary tumor transforming gene in glioma C6 cells. <i>Chinese-German Journal of Clinical Oncology</i> , 2008 , 7, 519-522		
53	Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2008 , 12, 589-603	6.4	97
52	Recurrence of urothelial carcinoma of the bladder: a role for insulin-like growth factor-II loss of imprinting and cytoplasmic E-cadherin immunolocalization. <i>Clinical Cancer Research</i> , 2008 , 14, 6829-38	12.9	9
51	Bibliography. Current world literature. Kidney cancer. <i>Current Opinion in Urology</i> , 2008 , 18, 540-5	2.8	
50	Novel agents for advanced bladder cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2009 , 1, 37-50	5.4	
49	Physical activity, obesity and risk for esophageal adenocarcinoma. <i>Future Oncology</i> , 2009 , 5, 1051-63	3.6	21
48	Molecular mechanisms of TRP regulation in tumor growth and metastasis. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2009 , 1793, 953-8	4.9	82
47	Urothelial overexpression of insulin-like growth factor-1 increases susceptibility to p-cresidine-induced bladder carcinogenesis in transgenic mice. <i>Molecular Carcinogenesis</i> , 2009 , 48, 671-7 ⁵		11
46	Insulin-like growth factor type I receptor gene expression and obesity in esophageal adenocarcinoma. <i>Molecular Carcinogenesis</i> , 2009 , 48, 982-8	5	10
45	A polymorphic variant of the insulin-like growth factor type I receptor gene modifies risk of obesity for esophageal adenocarcinoma. <i>Cancer Epidemiology</i> , 2009 , 33, 37-40	2.8	29
44	Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. <i>Current Cancer Drug Targets</i> , 2009 , 9, 748-60	2.8	14 ⁰
43	Selection of affibody molecules to the ligand-binding site of the insulin-like growth factor-1 receptor. <i>Biotechnology and Applied Biochemistry</i> , 2010 , 55, 99-109	2.8	28
42	Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. <i>BJU International</i> , 2010 , 105, 317-21	5.6	9 ⁰
41	Biomedical text summarization to support genetic database curation: using Semantic MEDLINE to create a secondary database of genetic information. <i>Journal of the Medical Library Association: JMLA</i> , 2010 , 98, 273-81	1.4	9
4 ⁰	Serum interleukin-8 and insulin like growth factor-1 in Egyptian bladder cancer patients. <i>Cancer Biomarkers</i> , 2010 , 6, 105-10	3.8	8
39	MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010 , 28, 635-41	2.8	36
38	The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin. <i>American Journal of Pathology</i> , 2010 , 176, 2997-3006	5.8	75

37	Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. <i>Lancet Oncology, The</i> , 2010 , 11, 861-70	21.7	105
36	TRPV channels in tumor growth and progression. <i>Advances in Experimental Medicine and Biology</i> , 2011 , 704, 947-67	3.6	50
35	High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt. <i>Diabetes Research and Clinical Practice</i> , 2011 , 91, 177-82	7.4	28
34	MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. <i>Cancer Letters</i> , 2011 , 307, 211-20	9.9	114
33	Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. <i>Molecular and Cellular Endocrinology</i> , 2011 , 344, 1-24	4.4	60
32	The association between bladder cancer and a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) gene. <i>Archives of Toxicology</i> , 2011 , 85, 1209-18	5.8	17
31	Dynamic summarization of bibliographic-based data. <i>BMC Medical Informatics and Decision Making</i> , 2011 , 11, 6	3.6	8
30	Personalized therapy for urothelial cancer: review of the clinical evidence. <i>Clinical Investigation</i> , 2011 , 1, 546-555		6
29	Anti-angiogenic effects of the superantigen staphylococcal enterotoxin B and bacillus Calmette-Guérin immunotherapy for nonmuscle invasive bladder cancer. <i>Journal of Urology</i> , 2012 , 187, 438-45	2.5	29
28	Neoadjuvant chemotherapy for invasive bladder cancer. <i>Current Urology Reports</i> , 2012 , 13, 136-46	2.9	16
27	Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. <i>BJU International</i> , 2013 , 112, 1105-12	5.6	53
26	Insulin use and smoking jointly increase the risk of bladder cancer mortality in patients with type 2 diabetes. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 508-14	3.3	13
25	Oncogenic and anti-oncogenic effects of transient receptor potential channels. <i>Current Topics in Medicinal Chemistry</i> , 2013 , 13, 344-66	3	27
24	Expression of insulin-like growth factor-1 receptor in conventional cutaneous squamous cell carcinoma with different histological grades of differentiation. <i>American Journal of Dermatopathology</i> , 2014 , 36, 807-11	0.9	5
23	Does Pioglitazone Increase the Risk of Bladder Cancer in Japanese Diabetic Patients?. <i>Medical & Surgical Urology</i> , 2014 , 04,		
22	Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFI, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2014 , 20, 4747-57	12.9	41
21	Insulin-like growth factor-1 receptor overexpression is associated with outcome in invasive urothelial carcinoma of urinary bladder: a retrospective study of patients treated using radical cystectomy. <i>Urology</i> , 2014 , 83, 1444.e1-6	1.6	12
20	New treatments for bladder cancer: when will we make progress?. <i>Current Treatment Options in Oncology</i> , 2014 , 15, 99-114	5.4	15

19	Molecular Testing in Urothelial Tumors. 2014 , 301-317		
18	MicroRNA-145 directly targets the insulin-like growth factor receptor I in human bladder cancer cells. <i>FEBS Letters</i> , 2014 , 588, 3180-5	3.8	35
17	MicroRNA-490-5p is a novel tumor suppressor targeting c-FOS in human bladder cancer. <i>Archives of Medical Science</i> , 2015 , 11, 561-9	2.9	37
16	Competing risks data analysis with high-dimensional covariates: an application in bladder cancer. <i>Genomics, Proteomics and Bioinformatics</i> , 2015 , 13, 169-76	6.5	19
15	Metformin can block precancerous progression to invasive tumors of bladder through inhibiting STAT3-mediated signaling pathways. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 77	12.8	31
14	miR-143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF-1R signaling. <i>Oncology Letters</i> , 2017 , 13, 435-440	2.6	41
13	IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer. <i>BMC Cancer</i> , 2017 , 17, 636	4.8	11
12	Targeting IGF1R pathway in cancer with microRNAs: How close are we?. <i>RNA Biology</i> , 2018 , 15, 320-326	4.8	10
11	MicroRNA-539 inhibits the proliferation and invasion of bladder cancer cells by regulating IGF-1R. <i>Molecular Medicine Reports</i> , 2018 , 17, 4917-4924	2.9	5
10	L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. <i>BioMed Research International</i> , 2018 , 2018, 1691428	3	140
9	Pre-diagnostic circulating insulin-like growth factor-I and bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition. <i>International Journal of Cancer</i> , 2018 , 143, 2351-2358	7.5	11
8	Influence of diabetes on the risk of urothelial cancer according to body mass index: a 10-year nationwide population-based observational study. <i>Journal of Cancer</i> , 2018 , 9, 488-493	4.5	5
7	Insulin-like growth factor-1 receptor expression in upper tract urothelial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019 , 474, 21-27	5.1	6
6	Role of tyrosine kinases in bladder cancer progression: an overview. <i>Cell Communication and Signaling</i> , 2020 , 18, 127	7.5	9
5	Regularized Weighted Nonparametric Likelihood Approach for High-Dimension Sparse Subdistribution Hazards Model for Competing Risk Data. <i>Computational and Mathematical Methods in Medicine</i> , 2021 , 2021, 5169052	2.8	0
4	High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancer. <i>Aging</i> , 2020 , 12, 2030-2048	5.6	10
3	Predicting the Survival Time for Bladder Cancer Using an Additive Hazards Model in Microarray Data. <i>Iranian Journal of Public Health</i> , 2016 , 45, 239-48	0.7	2
2	Prognostic impact of insulin-like growth factor-I and its binding proteins, insulin-like growth factor-I binding protein-2 and -3, on adverse histopathological features and survival outcomes after radical cystectomy. <i>International Journal of Urology</i> , 2022 ,	2.3	1

- 1 The Association between Diabetes Medication Use and Tumour Characteristics at Diagnosis in Patients with Urothelial Carcinoma: A Retrospective Registry-Based Study1. **2023**, 9, 73-82

o